Capromorelin

From Wikipedia, the free encyclopedia

Template:Short description Template:DMCA

Page Module:Message box/ambox.css has no content.

Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Capromorelin
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesEntyce, Elura, Eluracat
Other namesCP-424,391
License dataPage Template:Plainlist/styles.css has no content.
Routes of
administration		By mouth
ATCvet codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Elimination half-life2.4 hours[4]
Identifiers
  • N-[(2R)-1-[(3aR)-2-methyl-3-oxo-3a-(phenylmethyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-(phenylmethoxy)propan-2-yl]-2-amino-2-methylpropanamide
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC28H35N5O4
Molar mass505.619 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3=NN(C(=O)[C@@]3(C2)CC4=CC=CC=C4)C)N
  • InChI=1S/C28H35N5O4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22H,14-19,29H2,1-3H3,(H,30,35)/t22-,28-/m1/s1 checkY
  • Key:KVLLHLWBPNCVNR-SKCUWOTOSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Capromorelin, sold under the brand names Entyce and Elura, is a medication used for the management of weight loss in cats and dogs.[5][6] Capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain.[2]

Capromorelin was developed by Pfizer.[7][8]

Capromorelin was approved for veterinary use in the United States in May 2016.[9] It is the second drug approved for the management of weight loss in cats and the first drug approved specifically for the management of weight loss in cats with chronic kidney disease.[2]

Research

Capromorelin functions to stimulate the secretion of growth hormone and as a ghrelin mimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. Studies have shown the drug to directly raise insulin growth factor 1 (IGF-1) and growth hormone levels.[10]

In a one-year treatment trial (starting 1999) with 395 seniors between 65 and 84 years old, patients who received the drug gained an average of 3 lb (1.4 kg) in lean body mass in the first six months and also were better able to walk in a straight line in a test of balance, strength and coordination. After 12 months, patients receiving capromorelin also had an improved ability to climb stairs; however, the results were not good enough to continue the trial for the second planned year.[11]

As of 2017, capromorelin studies in humans had been discontinued.[12]

Veterinary uses

Capromorelin is indicated for the management of weight loss in cats and dogs.[2]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Notice: Multiple additions to the Prescription Drug List (PDL) [2024-08-13]". Health Canada. 13 August 2024. Retrieved 15 August 2024.
  2. ^ a b c d Page Module:Citation/CS1/styles.css has no content."FDA Approves Elura for Weight Loss in Cats with Chronic Kidney Disease". U.S. Food and Drug Administration. 19 October 2020. Archived from the original on 1 November 2020. Retrieved 12 December 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ Page Module:Citation/CS1/styles.css has no content."Eluracat EPAR". European Medicines Agency. 22 May 2023. Retrieved 24 May 2024.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Khojasteh-Bakht SC, O'donnell JP, Fouda HG, Potchoiba MJ (January 2005). "Metabolism, pharmacokinetics, tissue distribution, and excretion of [14C]CP-424391 in rats". Drug Metabolism and Disposition. 33 (1): 190–9. doi:10.1124/dmd.104.001065. PMID 15486077. S2CID 20760627.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Entyce". U.S. Food and Drug Administration (FDA). Retrieved 12 December 2022.
  6. ^ Page Module:Citation/CS1/styles.css has no content."Elura". U.S. Food and Drug Administration (FDA). Retrieved 12 December 2022.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Carpino PA, Lefker BA, Toler SM, Pan LC, Hadcock JR, Murray MC, et al. (November 2002). "Discovery and biological characterization of capromorelin analogues with extended half-lives". Bioorganic & Medicinal Chemistry Letters. 12 (22): 3279–82. doi:10.1016/s0960-894x(02)00734-5. PMID 12392732.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Carpino PA, Lefker BA, Toler SM, Pan LC, Hadcock JR, Cook ER, et al. (February 2003). "Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin". Bioorganic & Medicinal Chemistry. 11 (4): 581–90. doi:10.1016/s0968-0896(02)00433-9. PMID 12538023.
  9. ^ Page Module:Citation/CS1/styles.css has no content."Aratana Therapeutics Granted FDA Approval of Entyce (capromorelin oral solution)". Aratana Therapeutics. 17 May 2016. Retrieved 12 December 2022 – via PR Newswire.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Pan LC, Carpino PA, Lefker BA, Ragan JA, Toler SM, Pettersen JC, et al. (February 2001). "Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue". Endocrine. 14 (1): 121–32. doi:10.1385/ENDO:14:1:121. PMID 11322494. S2CID 46978604.
  11. ^ Page Module:Citation/CS1/styles.css has no content.White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, et al. (April 2009). "Effects of an oral growth hormone secretagogue in older adults". The Journal of Clinical Endocrinology and Metabolism. 94 (4): 1198–206. doi:10.1210/jc.2008-0632. PMID 19174493.
  12. ^ Page Module:Citation/CS1/styles.css has no content.Rhodes L, Zollers B, Wofford JA, Heinen E (February 2018). "Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs". Veterinary Medicine and Science. 4 (1): 3–16. doi:10.1002/vms3.83. PMC 5813110. PMID 29468076.

Template:GH/IGF-1 axis signaling modulators

Retrieved from "https://cosmopedia.co/index.php?title=Capromorelin&oldid=3014910"